1. Scrip
  2. >>Business
  3. >>Strategy

Pharming Regains Rights To Ruconest, Seizing More Control Over Its Destiny

 
• By Sten Stovall

The European specialty pharma will pay $60m upfront to Valeant to reacquire the rights to commercialize the hereditary angioedema treatment in North America.

SC1608_Man-White-Board-Transaction_1200x675

Pharming NV has the opportunity to achieve profitability in 2017, three years sooner than expected by reacquiring the rights to commercialize its hereditary angioedema (HAE) treatment in North America, the firm said. The Netherlands-based specialty pharma announced Aug. 9 that it reached an agreement with Valeant Pharmaceuticals International Inc. to buy back rights to Ruconest (recombinant human C1 esterase inhibitor) in the US, Mexico and Canada for $60m upfront.

The deal will give Pharming control over the commercialization of Ruconest, which Valeant hadn’t been prioritizing given the recent upheaval at the company, including a change in leadership at the top spot. Valeant acquired the North American license to Ruconest through the acquisition of Salix Pharmaceuticals Ltd

More from Strategy

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

More from Business

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.